AN OPEN-LABEL RANDOMIZED CONTROL TRIAL TO COMPARE THE EFFICACY OF VIRECHANA & GOMUTRA-HARITAKI VERSUS URSODEOXYCHOLIC ACID (UDCA) ON NAFLD FIBROSIS SCORE AMONG NAFLD PATIENTS

AD0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•NAFLD confirmed by NFS score with or without having symptoms like fatigue, mild discomfort in the upper quadrant of abdomen etc.
•NAFLD patients who are refractive to standard drugs of treatment.
•Willing and able to participate in study and given written informed consent.
•Yogya for Virechana

•Excessive use of alcohol within 2 years prior to initial screening. Or alcohol intake more than 20g per day for female and less than 30 g per day for males
•Uncontrolled systemic disease or medically unstable and major psychological disorders
•Any dysfunction of liver besides non-alcoholic fatty liver disease like viral hepatitis liver parenchymal disease, ascites, portal hypertension, Hepato-cellular carcinoma, Auto- immune hepatitis, Primary biliary cirrhosis, Wilsons disease, and liver transplantation or any other conditions interfering with the result of the treatment Alcoholic fatty liver disease patient
•Pregnant/lactating female
•Virechana ayogya

发起方